Gregory L. Moore

发表

A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens

G. A. Lazar, G. Lazar, S. Karki, 2011, mAbs.

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

G. A. Lazar, G. Lazar, S. Karki, 2010, mAbs.

Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb.

J. Desjarlais, D. Szymkowski, U. Muchhal, 2012, Immunology letters.

A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats.

J. Desjarlais, Alex Nisthal, R. Rashid, 2019, Methods.

Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody.

J. Desjarlais, D. Szymkowski, H. Horton, 2012, The Journal of allergy and clinical immunology.

Immunotherapy with Long-Lived Anti-CD123 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia

J. Desjarlais, D. Szymkowski, R. Rashid, 2014 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Engineering fully human monoclonal antibodies from murine variable regions.

John R Desjarlais, Greg A Lazar, J. Desjarlais, 2010, Journal of molecular biology.

Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies.

G. A. Lazar, John R Desjarlais, Igor Vostiar, 2008, Molecular immunology.

Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell–recruiting Antibody Optimized for Cytotoxicity and Cytokine Release

J. Desjarlais, A. Coxon, J. Canon, 2019, Clinical Cancer Research.

Tuning T Cell Affinity Improves Efficacy and Safety of Anti-CD38 × Anti-CD3 Bispecific Antibodies in Monkeys - a Potential Therapy for Multiple Myeloma

J. Desjarlais, Suzanne Schubbert, D. Szymkowski, 2015 .

Immunotherapy with Long-Lived Anti-CD38 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human Myeloma Cell Lines and CD38+ Cells in Monkeys: A Potential Therapy for Multiple Myeloma

J. Desjarlais, D. Szymkowski, R. Rashid, 2014 .

Abstract 5565: Potency-reduced IL15/IL15Rα heterodimeric Fc-fusions display enhanced in vivo activity through increased exposure

J. Desjarlais, Suzanne Schubbert, R. Varma, 2018, Clinical Research (Excluding Clinical Trials).

Abstract 2784: Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation

J. Desjarlais, Alex Nisthal, R. Varma, 2018, Immunology.

Immune suppression in cynomolgus monkeys by XPro9523

J. Desjarlais, G. Lazar, D. Szymkowski, 2013, mAbs.